AP Biosciences Inc (6945.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan · ISIN TW0006945009

Price
117.50 TWD
Market cap
11.46 bn TWD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-34.99 %
Return on assets (ROA)
-32.58 %

AP Biosciences Inc financials

Fiscal year20242025
Revenue0.00 TWD0.00 TWD
Gross profit-17.48 m TWD0.00 TWD
Operating income-439.06 m TWD-456.38 m TWD
EBIT-421.10 m TWD-443.34 m TWD
Net income-422.75 m TWD-444.77 m TWD
Diluted EPS – continuing operations-5.61 TWD-5.20 TWD

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About AP Biosciences Inc

AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. It caters to healthcare and biotechnology industries. AP Biosciences, Inc. has strategic collaboration with Delos Capital to discover and develop novel immune-related drug candidates through early clinical proof of concept. The company was founded in 2013 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.